AER 271

Drug Profile

AER 271

Alternative Names: AER-271

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aeromics
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Aquaporin 4-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Brain oedema

Most Recent Events

  • 25 Jul 2018 Aeromics plans a phase II trial for Cerebral edema in severe, acute ischemic stroke with large hemispheric infarction (LHI) in third quarter of 2019
  • 09 Jul 2018 Phase-I clinical trials in Brain oedema (In volunteers) in USA (IV)
  • 01 Dec 2017 Aeromics files an IND application for AER 271 for Brain edema (Aeromics company website, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top